instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: "The sight of the moon's shadow passing directly in front of the sun, blotting out all but the halo-like solar corona, may draw the largest live audience for a celestial event in human history. When those watching via broadcast and online media are factored into the mix, the spectacle will likely smash records. "It will certainly be the most observed total eclipse in history," astronomer Rick Fienberg of the American Astronomical Society (AAS) said last week. The eclipse begins its cross-country trajectory over the Pacific Coast of Oregon in late morning. It will reach South Carolina's Atlantic shore some 90 minutes later. The total eclipse of the sun is considered one of the most spell-binding phenomena in nature but it rarely occurs over a wide swath of land, let alone one of the world's most heavily populated countries at the height of summer. In terms of audience potential, it is hard to top the United States, with its mobile and affluent population, even though the direct path is mostly over rural areas, towns and small cities. The largest is Nashville, Tennessee, a city of 660,000 residents. Even so the advent of social media and inexpensive high-tech optics have boosted public awareness, assuring what many U.S. experts predict will be unprecedented viewership for the so-called "Great American Eclipse." Some might take issue with that prediction, citing a solar eclipse visible over parts of India, Nepal, Bangladesh and central China in July 2009. National Geographic estimated 30 million people in Shanghai and Hangzhou alone were in its path that day. On Monday, the deepest part of the shadow, or umbra, cast by the moon will fall over a 70-mile-wide (113-km-wide), 2,500-mile-long (4,000-km-long) ""path of totality"" traversing 14 states. The 12 million people who live there can view the eclipse at its fullest merely by walking outside and looking up, weather permitting. (tmsnrt.rs/2fNQHFb) LIVESTREAMING AND PRICE-GOUGING Some 200 million Americans reside within a day's drive of the totality zone, and as many as 7 million, experts say, are expected to converge on towns and campgrounds along the narrow corridor for the event. Many are attending multiday festivals featuring music, yoga and astronomy lectures. Millions more could potentially watch in real time as the eclipse is captured by video cameras mounted on 50 high-altitude balloons and streamed online in a joint project between NASA and Montana State University. A partial eclipse will appear throughout North America. Adding further to the excitement is the wide availability of affordable solar-safe sunglasses produced by the millions and selling so fast that suppliers were running out of stock. The owner of one leading manufacturer reported price gouging by second-hand dealers who were buying up large supplies and reselling them over the internet at a huge mark-up. Not all the hoopla will unfold on dry land. Welsh pop singer Bonnie Tyler is slated to perform her 1983s hit single "Total Eclipse of the Heart" aboard a cruise liner as the vessel sails into the path of totality from Florida on Monday. Back on the ground, forest rangers, police and city managers in the total eclipse zone are bracing for a crush of travelers they fear will cause epic traffic jams and heighten wildfire hazards. "Imagine 20 Woodstock festivals occurring simultaneously across the nation," Michael Zeiler, an AAS advisory panel member wrote on his website, GreatAmericanEclipse.com, referring to the famously chaotic 1969 outdoor rock extravaganza in upstate New York. Hundreds of residents in a prime-viewing area in Oregon had to evacuate on Saturday under threat from a wildfire raging in the Deschutes National Forest, according to InciWeb fire-tracking website. The so-called Milli Fire, which has scorched more than 7,8OO acres (3,162 hectare), is one of seven burning in Oregon, Montana and Idaho, three of the states crossed by the totality path. Zeiler, an avowed "eclipse chaser" who made the 650-mile (1,046-km) drive from his New Mexico home to Wyoming for a choice view, said South Carolina is likely to see the greatest influx as the destination state closest to the entire U.S. Eastern seaboard. Monday's event will be the first total solar eclipse spanning the entire continental United States since 1918 and the first visible anywhere in the Lower 48 states in 38 years. The next one over North America is due in just seven years, in April 2024." Claim: Millions of Americans to gaze upon Monday's once-in-a-lifetime eclipse.
answer:
Twilight will fall at midday on Monday, stars will glimmer and birds will roost in an eerie stillness as millions of Americans and visitors witness the first total solar eclipse to traverse the United States from coast to coast in 99 years.

question:
Paragraph: The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany's Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumor started, increasingly helped by the growing knowledge of cancer's complex genetic drivers. Under the tumor-agnostic approach, also known as pan-tumor, drugmakers skip the organ-of-origin perspective and regroup patients based only on signature genetic mutations, but success in real life will depend on the fast spread of comprehensive gene-sequencing tools for tissue samples. Individually, the mutations are so rare that cancer units are seen as unlikely to run dedicated tests for each. Roche's Foundation Medicine supplies the comprehensive kits, competing with Thermo Fisher Scientific and Caris Life Sciences. "It's one of the reasons we acquired Foundation Medicine, to make this comprehensive genomic profiling routine and upfront in the course of the disease," said Daniel O'Day, the head of Roche's Pharmaceuticals division. Loxo's larotrectinib pill, co-developed with Bayer, was last year shown to shrink tumors in 75 percent of patients with the NTRK fusion gene anomaly, occurring in the lung, pancreas, or more than a dozen other organs. On Sunday, the response rate to larotrectinib within an enlarged group of 122 trial participants - up from 55 initially and now spanning 24 tumor types - was shown to be 81 percent. Roche said the readings from the two NTRK fusion trials were not comparable because they are made up of different patient types. Loxo's study, for instance, included some cancers in children, while Roche plans to investigate those separately. The Roche compound is designed to tackle several oncogenic mutations and last month, it unveiled data here on entrectinib pushing back tumors in 77 percent of lung cancer patients with a mutation called ROS1. Merck & Co's Keytruda in May last year became the first drug to win approval for pan-tumor use, though that remains a relatively small market for the mega-selling drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195. Roche Pharmaceutical's O'Day welcomed a wider field. "Both things have to happen: You need genomic profiling and you need enough targeted medicines to encourage physicians to make that diagnosis upfront very complete. This is the world we're entering," he said. Though response rates could encourage a race for more such drugs, the need for suitable gene mutations or fusions will be a tall order, said oncologist Ulrik Lassen of Copenhagen's Rigshospitalet, who co-authored the larotrectinib study. "You need to screen a lot of patients to find the needle in the haystack and the method is complicated, costly and time-consuming. When we get better at using these technologies, we can find more oncogenic fusions and companies will be smart enough to find the agents that target them." Roche acquired entrectinib as part of its takeover deal with U.S. cancer drug specialist Ignyta Inc for $1.7 billion, agreed in December last year. Immuno-oncology remains another major business area for Roche, which also released positive results on using its Tecentriq drug in a group of breast cancer patients with a particularly poor prognosis. Claim: Roche takes on Loxo, Bayer in gene-defined cancer class.
answer:
Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

question:
Paragraph: Research fields in which fetal tissue is used include HIV, childhood cancers, treatments that enlist the body's immune system to battle cancer, and the hunt for a vaccine against the Zika virus, a cause of birth defects. Republicans said alternatives to fetal tissue are available and should be used instead. Democrats said that view is at odds with science. Each side called on expert witnesses. "Most of my constituents don't understand when you harvest baby parts, why that is OK," said Rep. Mark Meadows, R-N.C., who chaired the hearing by the Oversight and Government Reform Committee. Meadows, leader of the conservative House Freedom Caucus, is one of President Donald Trump's biggest allies in Congress. But Rep. Gerry Connolly, D-Va., responded, "The consensus in the scientific community is that there is currently no adequate substitute for fetal tissue in all of the cutting-edge research for which it is used today." The government has funded research using fetal tissue for decades, under administrations of both political parties. Trump has gone out of his way to court social and religious conservatives among his staunchest supporters. The administration's new review of whether taxpayer dollars are being properly spent on fetal tissue research has raised alarms among medical investigators, who fear their work will be stopped to satisfy anti-abortion activists. Under Secretary Alex Azar, the Health and Human Services Department says it is trying to balance "pro-life" and "pro-science" imperatives in its ongoing audit of fetal tissue research. Azar's office said in a statement that the National Institutes of Health put a pause on procurement of new human fetal tissue in the fall, after the audit was announced. The department says research with fetal tissue already on hand was allowed to proceed, and that it never intended to stop research. The HHS statement left open the possibility of procuring new fetal tissue to prevent research projects from being interrupted. Research involving fetal tissue accounted for $98 million in NIH grants and projects during the 2017 fiscal year, a small fraction of the agency's overall research budget. NIH said that $98 million figure represents the entire budget for the grants at issue, even if only a portion of a particular grant was devoted to fetal tissue research. HHS has not announced a timeline for completing its audit. Fetal tissue is used to produce research mice that model how the human immune system works. The tissue, from elective abortions, would otherwise be discarded. Biochemist Tara Sander Lee told the committee that alternatives to fetal tissue are available and can be used. "We do not need fetal body parts from aborted babies to achieve future scientific and medical advancements," said Sander Lee, with the Charlotte Lozier Institute, which is opposed to abortion. Tissues from infants who have to undergo heart surgery are among the alternatives, she said. But neuroscientist Sally Temple, testifying on behalf of the International Society for Stem Cell Research, told lawmakers that alternatives to fetal tissue are simply not suitable for every disease and condition being studied. "The consensus opinion is that those alternatives are not sufficient," she said. Temple explained that tissue samples from different stages of the life cycle are not interchangeable. "It is not the same material," she said. "It is a different developmental stage. It has unique properties." Temple said researchers would readily use alternatives to fetal tissue if that was suitable. Claim: Renewed battle over using fetal tissue in medical research.
answer:
Lawmakers clashed over science, ethics and politics at a House hearing Thursday on using fetal tissue in critically important medical research, as the Trump administration reviews the government's ongoing support for such studies.